AR and breast carcinoma: Furthermore, reduced miR-16-5p, miR-9-5p, and miR-195 enhanced breast cancer cell proliferation, and accelerated the cell cycle by targeting AKT3 (65), androgen receptor signaling (66), and cyclin E1 (CCNE1) (67), respectively.